Resource Library

Whitepapers

S-Glyn™ : Optimizing N-Glycan profiles and their effector functions using a Design-of-Experiments approach

Optimizing N-Glycan profiles and their effector functions using a Design-of-Experiments approach


A clear understanding of a molecule's N-glycan profiles and their effector functions is fundamental for a successful IND journey, given that glycosylation during cell culture can impact the biological activity of the drug substance.

 

In this whitepaper, Junyong Park, Lead Scientist in Upstream Development highlights how our proprietary platform, S-Glyn™ evaluates N-glycan profiles and optimizes effector functions by leveraging a design-of-experiments (DoE) approach, resulting in streamlined development timelines. DoE and statistical analysis can be used to swiftly optimize and predict glycosylation patterns while deepening process knowledge and understanding. 

 

DoE Studies for N-Glycan Optimization


Mammalian glycan structures are closely linked to immune functions. With the growing understanding of the relationships between abnormal glycan profiles and human diseases, glycoengineering has been widely adapted for antibody therapeutic development in oncology and immunology. CMC development with such antibody therapeutics is often challenged by stringent timelines. Identifying the myriad posttranslational modifications (PTMs) that can impact safety and efficacy is a complex and time-consuming aspect of that journey. Thoughtful application of design-of-experiments (DoE) strategies can significantly accelerate this activity. Here, we describe a DoE approach for the analysis of N-glycan profiles resulting from glycosylation and the relevant antibody effector functions that can impact drug performance. This work can be completed alongside process development and clinical material manufacturing, thereby reducing development timelines.

 

Optimizing N-Glycan profiles and their effector functions using a Design-of-Experiments approach


A clear understanding of a molecule's N-glycan profiles and their effector functions is fundamental for a successful IND journey, given that glycosylation during cell culture can impact the biological activity of the drug substance.

 

In this whitepaper, Junyong Park, Lead Scientist in Upstream Development highlights how our proprietary platform, S-Glyn™ evaluates N-glycan profiles and optimizes effector functions by leveraging a design-of-experiments (DoE) approach, resulting in streamlined development timelines. DoE and statistical analysis can be used to swiftly optimize and predict glycosylation patterns while deepening process knowledge and understanding. 

 

DoE Studies for N-Glycan Optimization


Mammalian glycan structures are closely linked to immune functions. With the growing understanding of the relationships between abnormal glycan profiles and human diseases, glycoengineering has been widely adapted for antibody therapeutic development in oncology and immunology. CMC development with such antibody therapeutics is often challenged by stringent timelines. Identifying the myriad posttranslational modifications (PTMs) that can impact safety and efficacy is a complex and time-consuming aspect of that journey. Thoughtful application of design-of-experiments (DoE) strategies can significantly accelerate this activity. Here, we describe a DoE approach for the analysis of N-glycan profiles resulting from glycosylation and the relevant antibody effector functions that can impact drug performance. This work can be completed alongside process development and clinical material manufacturing, thereby reducing development timelines.

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION